AbbVie (ABBV) expects its investigational drug Risankizumab, which was licensed from Boehringer Ingelheim this year and is currently being tested in Phase 3 clinical trials, to be a transformative therapy for psoriasis.
The drug has also demonstrated positive results as a therapy for Crohn’s disease in Phase 2 clinical trials, and AbbVie plans to further test the drug for the treatment of ulcerative colitis. In addition to its high efficacy, Risankizumab boasts high convenience of use.
Psoriasis Phase 2 results
The left panel in the chart above shows that based on Phase 2 clinical trial results, compared to peers such as Humira, Johnson & Johnson’s (JNJ) Stelara and Guselkumab (both through its subsidiary Janssen Biotech), Novartis’s (NVS) Cosentyx, and Eli Lilly’s (LLY) Ixekizumab, Risankizumab has managed to demonstrate a 90% response rate in a greater percentage of psoriasis patients after 12 weeks of therapy.
According to the right panel in the chart, Risankizumab also managed to demonstrate total skin clearance—or a 100% response rate—in around 50% of tested patients.
Risankizumab is being tested as a dose delivered once every 12 weeks, and it’s much more convenient to use than its closest competitor, Ixekizumab, in terms of ease of dosage. The latter is administered once a week.
If Risankizumab manages to secure regulatory approvals, AbbVie’s share price could rise, as could the price of the Health Care Select Sector SPDR ETF (XLV). AbbVie makes up about 3.8% of XLV’s total portfolio holdings.
Risankizumab has managed to demonstrate at least as much efficacy as displayed by other investigational and existing drugs for the treatment of Crohn’s disease. About 20% of patients tested in the drug’s Phase 2 trial also managed to display endoscopic remission after 12 treatments. This has further increased AbbVie’s confidence in the efficacy of the drug, which is expected to enter Phase 3 trials in late 2016 or early 2017.
In the next article, we’ll explore AbbVie’s research programs for the investigational immunology drug ABT-494.